Haemodynamic effects of atrial natriuretic peptide in hypoxic chronic obstructive pulmonary disease

T K Rogers, W Sheedy, J Waterhouse, P Howard, A H Morice

Abstract

Background — Pulmonary artery pressure is elevated in patients with advanced chronic obstructive pulmonary disease (COPD). Release of atrial natriuretic peptide (ANP) is increased in pulmonary hypertension and this hormone may both selectively vasodilate pulmonary vessels and inhibit pulmonary vascular remodelling. The hypothesis that ANP has a physiological role in protection of the pulmonary circulation from pressure overload, and that it may be beneficial in patients with COPD, has been examined.

Methods — Ten patients with hypoxic COPD were infused for 30 minute periods with saline followed by ANP at 0.4, 2, and 10 pmol/kg/min respectively via a pulmonary artery catheter whilst monitoring haemodynamics and oxygenation.

Results — Levels of immunoreactive ANP (irANP) increased from a mean (SD) of 23 (15) pmol/l to a maximum of 94 (41) pmol/l. Neither systemic blood pressure, cardiac output nor total systemic vascular resistance showed any correlation with irANP levels. There were negative correlations between levels of ANP and mean pulmonary artery pressure which fell from 28.7 to 25.9 mm Hg, pulmonary artery wedge pressure which fell from 6.5 to 4.6 mm Hg, and total pulmonary vascular resistance which fell from 489 to 428 dynes s cm⁻⁵. There was a small fall in PaCO₂, from 6.2 to 5.9 kPa, whilst venous admixture and oxygen delivery both increased non-significantly.

Conclusions — At these pathophysiological concentrations there was evidence that ANP selectively reduced right ventricular afterload. These data support the hypotheses that increased plasma levels of ANP may be beneficial in hypoxic COPD, and that endogenous ANP may ameliorate pulmonary hypertension in humans.

(Pulmonary vascular resistance is elevated in patients with advanced chronic obstructive pulmonary disease (COPD) associated with a progressive vascular remodelling of small pulmonary arteries and arterioles, although many other factors also contribute. As a result of increased afterload on the right ventricle, stroke volume and ejection fraction are depressed; cardiac output is maintained by a relative tachycardia. Oedema occurs during episodes of acute-on-chronic respiratory failure, a syndrome commonly known as “hypoxic cor pulmonale.” This is an important step in the natural history of the disease: without treatment 65% of patients die within five years of the first episode. The role of vasodilators is controversial. There have been several short and medium term trials of vasodilator treatment in the condition reviewed by Howard. Effects on arterial blood gases and cardiac output have been variable. Most agents have caused greater reduction of systemic than pulmonary vascular resistance. Some longer term trials have found that the pulmonary hypotensive effect disappeared with time, whilst others have found continued benefit at one year. No effect on prognosis has yet been shown.

There are three lines of evidence to suggest that atrial natriuretic peptide (ANP) may be helpful in patients with advanced COPD. Firstly, numerous studies in intact animals in animal isolated lung preparations, and in isolated animal and human vessels have suggested that the vasodilator activity of ANP may be selective for the pulmonary vascular bed. Secondly, there is evidence that ANP can inhibit vascular remodelling, both in vitro and in the rat model of hypoxic pulmonary hypertension. This has been achieved both by chronic infusion of ANP and by the inhibition of ANP metabolism with neutral endopeptidase inhibitors. Thirdly, the well known diuretic and natriuretic effects of ANP may have a value in reversing the episodic fluid retention. Against these possible benefits is the potential disadvantage that, by acutely antagonising hypoxic pulmonary vasoconstriction, ANP may impair ventilation-perfusion matching and exacerbate hypoxia.

In this study we have examined the response of patients with hypoxic COPD to levels of ANP seen in severe pulmonary hypertension. Physiological release was simulated by infusing ANP into the main pulmonary artery in 10 subjects. The hypotheses to be tested were (1) that these levels of ANP, achievable by pharmacological modification of ANP metabolism, have a beneficial effect on pulmonary haemodynamics in COPD; and (2) that ANP has a specific effect on the pulmonary vasculature. Finding the hypotheses to be correct would suggest that inhibitors of ANP metabolism may be of therapeutic use in COPD, and...
that the high concentrations of ANP found in severe pulmonary hypertension may have a homeostatic function.

Methods
PATIENTS
Local ethical committee approval for the study was obtained. A power calculation showed that, to allow an 80% chance of detecting a fall in pulmonary artery pressure (Ppa) of 5 mm Hg by a two tailed paired t test with \( \alpha = 0.05 \), assuming a variance of the difference between pairs of 28 (from Adnot et al\(^{39} \)), at least nine patients would be required. Ten patients were therefore enrolled, selected from a respiratory outpatient clinic and included after giving formal written consent.

Inclusion criteria
Patients were included in the study if they satisfied all the following conditions: severe chronic airflow obstruction with FEV\(_1\)/FVC less than 60%; history of more than 10 pack years of tobacco consumption; stable respiratory failure with \( \text{Pao}_2 < 8.0 \text{kPa} \).

Exclusion criteria
Patients were excluded if they had any clinical evidence of ischaemic or valvular heart disease, any significant intercurrent disease, or had had an acute exacerbation of COPD during the three months before the study. Because ANP is known to cause an increase in haematocrit as a result of a shift of fluid from the intravascular space, any patient with a haematocrit of \( > 50\% \) was also to have been excluded, although no otherwise eligible subject was excluded on the basis of this criterion.

STUDY PROTOCOL
Patients were seen by a dietician to establish a constant salt intake over the week before the study day, and were admitted to hospital either on the evening before or the morning of the study. On rising patients were asked to micturate. They were not given oxygen supplementation or diuretic treatment on the day of the study, but were allowed other morning medication and a light breakfast. They then remained nil by mouth until completion of the study. Just before commencement of the study patients were again asked to void the bladder, storing an aliquot of urine at \(-20°C\).

Right heart catheterisation was performed in an operating theatre under sterile conditions. A 7 French gauge, five lumen, flow directed, balloon tipped, thermodilution catheter (Criticath, Spectramed Inc) was introduced through a brachial or internal jugular vein. Placement of the catheter tip in the pulmonary artery was determined by monitoring the pressure trace during advancement, if necessary with the aid of an image intensifier. The catheter was clamped in the position at which a pulmonary artery wedge pressure could be recorded. After catheter insertion patients sat semirecumbent for the duration of the study.

A 21-gauge intravenous cannula (Viggo) was positioned in a forearm or vein for peripheral venous blood samples. Transcutaneous oxygen saturation (\( \text{SaO}_2 \)) and pulse rate were continuously monitored with a pulse oximeter (Minolta Pulsox-7). Systemic blood pressure was measured with a Dynamap sphygmomanometer on the contralateral arm. Cardiac output measurements were made in triplicate, each thermal bolus consisting of 10 ml of room temperature saline. Cardiac output was determined with a Gould Model SP2009B recorder and bedside computer. Arterial blood gas samples were taken from the radial artery during the baseline saline infusion and maximal ANP infusion.

ANP INFUSION
There were four infusion periods, each lasting 30 minutes. For the first period saline was infused at the same rate as that required for the maximum dose of ANP. Incremental doses of ANP were then infused, equivalent to 0.4, 2, and 10 pmol/kg/min (called ANP-1, ANP-2, and ANP-3, respectively). We have previously shown that these doses produce plasma levels within the pathophysiological range and have renal effects when infused into normal volunteers.\(^{39}\)

The following measurements were taken after 15 minutes of each infusion period: pulmonary artery pressure, cardiac output, pulse rate, systemic blood pressure, arterial oxygen saturation (\( \text{SaO}_2 \)), and mixed venous blood gas tensions. Venous blood samples were taken from the peripheral venous cannula for immediate centrifugation and were stored at \(-20°C\) for subsequent assay of plasma ANP concentration. Fifteen minutes after the end of the final infusion of ANP a further set of recordings was made and urine collected and stored at \(-20°C\).

MATERIALS
Human synthetic ANP (Sigma Chemical Company, Poole, Dorset) was dissolved in 0.05 mol/l acetic acid (FSA Laboratory Supplies, Loughborough) and sterilised by passage through a Millex GV, low protein binding filter (Millipore, Harrow, Middlesex), the first 1-0 ml being discarded. It was then diluted to 2 nmol/ml in a solution of 50% normal saline (Baxter, Thetford) and 50% Haemaccel (Hoechst, Hounslow, Middlesex) to minimise adsorption of ANP to surfaces. Vials containing 15 ml of the solution were frozen at \(-20°C\) until used.

Before infusion ANP was thawed and diluted to 0.5 pmol/l with normal saline. The solution was infused in a syringe driver (Vickers) via the "CVP medication" lumen of the pulmonary artery catheter.
ANP RADIOIMMUNOASSAY
Blood samples were centrifuged immediately at 4°C and 3000 rpm for 20 minutes. Plasma was aspirated and stored in polypropylene vials at −20°C. Extraction of plasma ANP was carried out using Sep-Pak C18 cartridges (Waters Associates). One millilitre of plasma was acidified with trifluoroacetic acid (0-1%) and applied to a primed cartridge which was then washed with 5 ml 0-1% trifluoroacetic acid and eluted with 2-0 ml of 70% acetonitrile. Samples were vacuum dried and stored at −20°C for up to one week until assayed. Alpha human ANP radioimmunoassay kits (RIK8798, Peninsula Laboratories Inc) were used. Plasma samples were reconstituted with 1 ml of the buffer and assayed in duplicate.

Between 20% and 40% of the label was bound in the absence of unlabelled peptide and 1-2% in the absence of antibody. The intra-assay coefficient of variation was 13% and the interassay coefficient of variation was 6%. The IC50 for the assays was 50-90 pg/ml. Recovery of iodine-125 was 70-90% using this extraction method. No correction was made for extraction losses.

DIRECT MEASUREMENTS OF ANP EFFECTS

Haemodynamic effects of ANP in hypoxic pulmonary artery pressure. Patient 5 was also included in the study.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age</th>
<th>Sex</th>
<th>Pack LTOT</th>
<th>FEV1 (l)</th>
<th>FEV1 (% pred)</th>
<th>FVC (l)</th>
<th>PaO2 (kPa)</th>
<th>PacO2 (kPa)</th>
<th>H* (mmol/l)</th>
<th>Past history of oedema</th>
<th>Baseline PPa (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>67</td>
<td>M</td>
<td>22</td>
<td>Yes</td>
<td>282</td>
<td>0-90</td>
<td>40</td>
<td>2-20</td>
<td>6-90</td>
<td>5-60</td>
<td>38</td>
</tr>
<tr>
<td>2</td>
<td>79</td>
<td>M</td>
<td>10</td>
<td>Yes</td>
<td>636</td>
<td>0-73</td>
<td>32</td>
<td>2-10</td>
<td>6-87</td>
<td>5-04</td>
<td>34</td>
</tr>
<tr>
<td>3</td>
<td>69</td>
<td>M</td>
<td>35</td>
<td>No</td>
<td>93</td>
<td>0-93</td>
<td>33</td>
<td>2-09</td>
<td>7-78</td>
<td>6-70</td>
<td>39</td>
</tr>
<tr>
<td>4</td>
<td>69</td>
<td>M</td>
<td>21</td>
<td>Yes</td>
<td>1685</td>
<td>1-03</td>
<td>47</td>
<td>2-06</td>
<td>5-69</td>
<td>7-00</td>
<td>39</td>
</tr>
<tr>
<td>5</td>
<td>65</td>
<td>M</td>
<td>35</td>
<td>Yes</td>
<td>1326</td>
<td>1-86</td>
<td>79</td>
<td>3-51</td>
<td>5-81</td>
<td>4-72</td>
<td>34</td>
</tr>
<tr>
<td>6</td>
<td>63</td>
<td>F</td>
<td>45</td>
<td>No</td>
<td>82</td>
<td>0-82</td>
<td>37</td>
<td>1-66</td>
<td>7-24</td>
<td>6-83</td>
<td>43</td>
</tr>
<tr>
<td>7</td>
<td>70</td>
<td>F</td>
<td>30</td>
<td>Yes</td>
<td>539</td>
<td>0-80</td>
<td>42</td>
<td>2-10</td>
<td>5-93</td>
<td>7-16</td>
<td>38</td>
</tr>
<tr>
<td>8</td>
<td>61</td>
<td>F</td>
<td>20</td>
<td>Yes</td>
<td>377</td>
<td>0-30</td>
<td>15</td>
<td>0-70</td>
<td>5-78</td>
<td>7-00</td>
<td>37</td>
</tr>
<tr>
<td>9</td>
<td>65</td>
<td>M</td>
<td>50</td>
<td>No</td>
<td>80</td>
<td>0-80</td>
<td>26</td>
<td>2-00</td>
<td>7-88</td>
<td>6-65</td>
<td>35</td>
</tr>
<tr>
<td>10</td>
<td>72</td>
<td>M</td>
<td>35</td>
<td>No</td>
<td>49</td>
<td>0-49</td>
<td>19</td>
<td>2-38</td>
<td>6-66</td>
<td>5-39</td>
<td>36</td>
</tr>
</tbody>
</table>

Mean = 68 30 6/10 808 0-87 37 2-08 6-74 6-21 37 5/10 30-0

LTOT = long term oxygen therapy; FEV1 = forced expiratory volume in one second; % pred = percentage of predicted; FVC = forced vital capacity; PPa = pulmonary artery pressure.

Six patients were receiving long term domiciliary oxygen therapy, two (nos 6 and 10) were about to commence it, and two did not have evidence of fibrotic lung disease.
sufficiently severe hypoxaemia to qualify (nos 3 and 9) having a $P_{aO_2}$ greater than 7.3 kPa. Five patients had a history of oedema, although none was in overt cor pulmonale during the study.

PLASMA ANP LEVELS

As can be seen in fig 1 there was a dose dependent increase in serum levels of irANP (ANOVA $p<1 \times 10^{-13}$). Both of the higher rates of ANP infusion (ANP-2 and ANP-3) resulted in significant increases, by 89% ($p<0.005$) and 422% ($p<0.0005$) of baseline values, respectively.

One patient (no. 4) showed an atypical response. The resting ANP level was the highest for the group at 50 pmol/l, and levels were not increased by subsequent ANP infusion. This subject also had the highest resting mean $P_{pa}$ at 37 mm Hg and was the only subject whose $P_{pa}$ did not fall during ANP infusion; indeed it rose to 40 mm Hg. He experienced a fall in $P_{aO_2}$ during ANP-3 from 6.6 to 6.1 kPa, and $P_{aCO_2}$ fell from 7.0 to 6.6 kPa.

HAEMODYNAMIC EFFECTS

Pulmonary haemodynamics

Haemodynamic effects of ANP infusion are shown in table 2. The baseline mean pulmonary artery pressure and total pulmonary vascular resistance were elevated in all patients (ranges 20–38 mm Hg and 292–740 dynes s cm$^{-5}$, respectively). Mean pulmonary artery pressure showed a significant, negative correlation with irANP levels, falling from a mean (SD) of 28.7 (6.4) mm Hg during saline infusion to 25.9 (6.9) mm Hg at maximum infusion rate ($r = -0.95$, $p<0.005$; figs 2 and 3). Total pulmonary vascular resistance was also significantly correlated, with a fall of 12% from 489 (168) to 428 (151) dynes s cm$^{-5}$ ($r = -0.46$, $p<0.005$; fig 4). There was no correlation with pulmonary arteriolar resistance which fell from 329 (125) to 299 (96) dynes s cm$^{-5}$ ($r = -0.11$, $p>0.4$; table 2).

Systemic haemodynamics

Neither cardiac index, total systemic vascular resistance, nor systemic blood pressure correlated with irANP levels (table 2). Total systemic vascular resistance fell by 5% from 1887 dynes s cm$^{-5}$ during saline infusion to 1799 dynes s cm$^{-5}$ at ANP-3 ($r = -0.07$, $p=0.98$). In four patients the $P_{PAW}$ was unobtainable, but none of the remaining patients had an elevated resting value (range 5.2–9 mm Hg). There was a significant correlation between ANP levels and pulmonary artery wedge pressure, which fell from 6.5 (1.1) to 4.6 (1.4) mm Hg at the maximum dose ($r = -0.80$, $p<0.001$; fig 5). Furthermore, $P_{PAW}$ was strongly correlated with both $P_{pa}$ ($r = 0.67$, $p<0.01$) and TPVR ($r = 0.60$, $p<0.01$) in the six subjects in whom it was measured.

GAS EXCHANGE

There was a small but significant fall in $P_{aCO_2}$ from 6.2 (0.9) to 5.9 (0.9) kPa, $p<0.0005$ (table 2). The mean $P_{aO_2}$ showed no significant change from 6.7 (0.8) kPa at baseline to 6.9 (0.9) kPa at ANP-3. Individual patients varied in their response: five patients $P_{aO_2}$ increased by a mean of 0.6 (range +0.3 to +0.8) kPa, and in five patients it fell by a mean of −0.4 (range −0.2 to −0.6) kPa. The oxygen saturation measured by pulse oximetry suggested a significant, positive correlation between ANP levels and $S_{aO_2}$ ($r = 0.42$, $p<0.01$).

To determine the right to left shunt fraction, mixed venous blood gases were assessed in nine patients. As might be expected shunt fraction, which is partly derived from $P_{aO_2}$, also showed a variable response to ANP infusion between patients, increasing in five and falling in four.

RENAL EFFECTS

Urinary volume was not assessed. However, creatinine concentration fell from 9.3 (3.9) to 5.9 (3.6) mmol/l ($p<0.02$), and the ratio of urinary sodium to creatinine rose from 12 (11) to 22 (12) ($p<0.002$).

ADVERSE EFFECTS

The ANP infusion was well tolerated. No patient required supplemental oxygen during the procedure. One patient felt transiently faint upon removal of the right heart catheter, associated with systemic hypotension. This resolved within three minutes and was typical of a vasovagal episode.

Discussion

As expected, all patients had evidence of a restricted pulmonary vascular bed with raised mean pulmonary artery pressures, total pulmonary vascular resistance and, in the six in whom it could be measured, elevated pulmonary arteriolar resistance. The normal $P_{PAW}$ measurements and normal cardiac index suggest that the left ventricular function of the group was unimpaired.

As we have previously found,$^{13}$ mean (SD)

---

**Figure 1** Mean (SD) immunoreactive plasma levels of ANP during different infusion periods: saline = saline at maximum infusion rate used; ANP-1 = 0.4 pmol/kg/min ANP; ANP-2 = 2 pmol/kg/min ANP; ANP-3 = 10 pmol/kg/min ANP; recovery = no infusion.
Table 2  Mean (SD) ANP levels, haemodynamic effects, and blood gas changes during ANP infusion

<table>
<thead>
<tr>
<th>Number of observations</th>
<th>Infusion period</th>
<th>r</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Saline</td>
<td>ANP-1</td>
<td>ANP-2</td>
</tr>
<tr>
<td>irANP (pmol/l)</td>
<td>10</td>
<td>18 (8)</td>
<td>21 (10)</td>
</tr>
<tr>
<td>Cardiac index (l/min/m²²)</td>
<td>10</td>
<td>2.80 (0.20)</td>
<td>2.83 (0.21)</td>
</tr>
<tr>
<td>SBPsys (mm Hg)</td>
<td>10</td>
<td>149 (12)</td>
<td>149 (13)</td>
</tr>
<tr>
<td>SBP dias (mm Hg)</td>
<td>10</td>
<td>90 (11)</td>
<td>89 (9)</td>
</tr>
<tr>
<td>Mean SBP (mm Hg)</td>
<td>10</td>
<td>112 (15)</td>
<td>110 (10)</td>
</tr>
<tr>
<td>TSVR (dynes cm⁻¹)</td>
<td>10</td>
<td>1887 (496)</td>
<td>1800 (332)</td>
</tr>
<tr>
<td>PPaw (mm Hg)</td>
<td>10</td>
<td>6.5 (1.1)</td>
<td>5.7 (1.3)</td>
</tr>
<tr>
<td>PPA syst (mm Hg)</td>
<td>10</td>
<td>45.9 (14.1)</td>
<td>45.4 (14.1)</td>
</tr>
<tr>
<td>PPA dias (mm Hg)</td>
<td>10</td>
<td>19.6 (5.5)</td>
<td>20.3 (5.4)</td>
</tr>
<tr>
<td>Mean PPA (mm Hg)</td>
<td>10</td>
<td>28.7 (6.4)</td>
<td>28.2 (7.2)</td>
</tr>
<tr>
<td>TPVR (dynes cm⁻¹)</td>
<td>10</td>
<td>489 (168)</td>
<td>464 (151)</td>
</tr>
<tr>
<td>PAR (dynes cm⁻¹)</td>
<td>6</td>
<td>329 (125)</td>
<td>337 (126)</td>
</tr>
<tr>
<td>Pulse rate (beats/min)</td>
<td>10</td>
<td>82 (10)</td>
<td>82 (9)</td>
</tr>
<tr>
<td>Sgot (%)</td>
<td>10</td>
<td>85.9 (10)</td>
<td>86.5 (9.9)</td>
</tr>
<tr>
<td>PacO₂ (kPa)</td>
<td>10</td>
<td>6.7 (0.9)</td>
<td>6.9 (0.9)</td>
</tr>
<tr>
<td>Shunt fraction (%)</td>
<td>9</td>
<td>16.4 (7.2)</td>
<td>15.8 (7.0)</td>
</tr>
</tbody>
</table>

irANP = immunoreactive ANP; SBP sys = systemic systolic blood pressure; SBP dias = systemic diastolic blood pressure; TSVR = total systemic vascular resistance; PPaw = pulmonary artery wedge pressure; PPA = mean pulmonary artery pressure; TPVR = total pulmonary vascular resistance; PAR = pulmonary arteriolar resistance. Infusions ANP-1, ANP-2, and ANP-3 were 0.4, 2, and 10 pmol/kg/min respectively.

Note: p and r values refer to linear regression analysis in groups for variables assessed during each infusion period, and to paired, two tailed Student’s tests for the variables assessed at two time points only.

baseline serum irANP levels were mildly elevated at 23 (15) pmol/l compared with the levels of less than 12 pmol/l found by our assay in normal subjects. Infusion of ANP was associated with a dose related increase in plasma irANP levels up to concentrations previously found in patients with severe pulmonary hypertension.³⁴ The primary endpoint of this study was to establish the effect of such pathophysiological levels of ANP on the pulmonary circulation in COPD. The observed fall in mean pulmonary artery pressure was modest, but correlated significantly with ANP levels. Our patients also showed a renal response to ANP as shown by the significant increase in urinary sodium to creatinine ratio, similar to that we have previously described in normal volunteers.³⁰

The reduction in TPVR was a result of the pulmonary artery pressure falling in the presence of a stable cardiac output. The reduction of right ventricular afterload appears to have been due in large part to the fall in PPaw, accounting for approximately 36% of the reduction in TPVR in the subjects in whom it was measurable. Indeed, a fall in PPaw has been a consistent finding when ANP has been infused variously into animals, normal human volunteers,⁵ and patients with heart failure.³⁶⁻³⁸ Pulmonary arteriolar resistance, representing the degree of vasoconstriction present in the pulmonary vascular bed, did not change significantly in the patients in whom it could be calculated. The data do not allow conclusions to be drawn on whether pulmonary vaso-dilatation occurred at these levels of irANP, and whether this mechanism contributed to the fall in right ventricular afterload.

Caution should be exercised in interpreting the significance of changes in the multiple secondary and derived endpoints examined in this study. However, there was little evidence for effects of the infusion on systemic haemodynamics, with the exception of PPaw and heart rate. ANP infusion was not associated with changes in systemic arterial pressure with or in total systemic vascular resistance (TSVR). TSVR is the result of both the pres-
Figure 4 Mean (SE) total pulmonary vascular resistance during different infusion periods. See legend to fig 1 for abbreviations.

Figure 5 Mean (SE) pulmonary artery wedge pressure during different infusion periods. See legend to fig 1 for abbreviations.

sure drop across the systemic circulation and right atrial pressure. Because right atrial pressure is lowered by ANP infusion, the lack of change in TSVR further suggests that relaxation did not occur in systemic resistance vessels.

Pulse rate showed a small but significant increase, probably accounting for cardiac output being maintained in the face of the observed fall in preload. The lack of an increase in cardiac output has also been found in experimental animals and normal human volunteers and distinguishes ANP from other vasodilators. The likely explanation is that ANP causes a reduction in cardiac preload and is a poor systemic vasodilator.

The fall in pulmonary vascular resistance was achieved without mean arterial oxygen tension falling, or a significant increase in venous admixture. No patient developed severe hypoxaemia or other adverse haemodynamic effects from ANP infusion. In agreement with a previous study, Pao₂ fell in all patients during ANP infusion, although this may have been attributable to anxiety or some other factor (see below). The unexpected finding of an improvement in shunt fraction in some of our patients may reflect the derived nature of this parameter. Alternative explanations include mild vasodilatation causing pulmonary blood flow to be diverted from units with very low ventilation-perfusion ratios to those with higher values, or to bronchodilatation improving the distribution of ventilation.

Interestingly, it has recently been reported that ANP infusion increased Pao₂ and reduced the alveolar-arterial oxygen difference in normal volunteers exposed to hypobaric hypoxia.

Patient no. 4 showed no increase in plasma levels of irANP during the infusion, had a high resting ANP level, and was alone in not showing a fall in pulmonary artery pressure. Although the lack of increase in irANP is unexplained, this does provide support for the changes in pulmonary haemodynamics observed in the remaining patients being a result of an increase in plasma ANP levels. Conversely, the fall in Pao₂ in this patient suggests that this change, which was seen in all patients, may not have been attributable to ANP.

One other study has examined the effect of ANP infusion in human pulmonary hypertension. Adnot et al infused incremental doses of ANP over 10 minute periods via a peripheral vein in a group of seven patients with hypoxic COPD. They achieved much higher peripheral blood irANP levels than in our study, with even the lowest dose increasing the concentration from a baseline value of 44 pmol/l up to 120 pmol/l. These higher plasma concentrations had a significant depressor effect on the systemic circulation. These authors also found evidence of pulmonary selectivity, however, with a much greater fall in pulmonary than systemic vascular resistance. As in our study they also found a fall in Pao₂, apparently due to an increase in minute ventilation. Despite this, and in contrast to our study, Pao₂ fell sharply and significantly; we agree with their conclusion that this was due to the more profound pulmonary vasodilatation they observed exacerbating ventilation-perfusion mismatching.

Several studies have shown that ANP levels are elevated in pulmonary hypertension, whether due to various lung diseases or to cardiac failure. In this study we have found evidence that the concentrations of ANP found in severe pulmonary hypertension may selectively reduce right ventricular afterload in patients with hypoxia COPD. Thus a negative feedback loop may exist in which ANP release is increased to ameliorate the harmful effects of pulmonary hypertension on the pulmonary vasculature and right heart. The beneficial acute effects of low dose ANP suggest that drugs which inhibit its metabolism may have therapeutic potential in COPD.

TKR was supported by a research fellowship from Bristol-Myers Squibb Pharmaceuticals Ltd. We are indebted to Mrs Margaret Ashley and Mrs Margaret Dugas for nursing help.

6. Whyte KF, Flelley DC. Can pulmonary vasodilators im-
Haemodynamic effects of ANP in hypoxic cor pulmonary disease

7 Seibold H, Bunjes D, Schmidt A, Hombach V. Pathophysio-
logical aspects of predominant preload lowering on pulmonary circulation, gas exchange, and the biventricu-
9 Agostoni P, Doria E, Galli C, Tamborini G, Guazzi MD. Nifedipine reduces pulmonary vascular pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pul-
10 Brelat T, Hedenstierna G, Nyquist O, Ripe E. The use of a
vasodilator, felodipine, as an adjuvant to long-term oxygen
11 Bruni BN, Berger HJ, Matthias RA, Mahler D, Pytlak L, Zaret BL. Contrasting effects of vasodilators (nitrorgly-
cerin, sodium nitroprusside, and hydralazine) on right ventricular performance in patients with chronic obstructive pul-
function and symptomatic effects of pirituberol in COPD. Respi
13 Adnot S, Chabrier PE, Brun-Buisson C, Viossat I, Braquet P. Atrial natriuretic factor attenuates the pulmonary pres-
16 Stewart AZ, Thompson JS, Rogers TK, Morice AH. Atrial
17 Ou LC, Sardella GL, Hill NS, Thron CD. Does atrial
natriuretic factor protect against right ventricular over-
19 Numana NA, Gillespie MN, Altieri R, Pulmonary vasore-
20 Rogers TK, Stewart AG, Morice AH. Effect of chronic
hypoxia on rat pulmonary resistance vessels: vasodila-
tion by atrial natriuretic peptide. Clin Sci 1992;83:723-
21 Lindberg F, Anderson KE. Vasodilator responses to
alpha-human-atrial natriuretic peptide in isolated omen-
22 Labat C, Norel X, Benveniste J, Brink C. Vasorelaxant
effects of atrial peptide II on isolated human pulmonary
23 Abell TJ, Richards AM, Hikam E, Spiteri EA, Yandle T. Atrial natriuretic factor inhibits proliferation of vascular
24 Jin H, Yang RH, Chen YF, Jackson RM, Oparil S. Atrial
natriuretic peptide attenuates the development of pul-
25 Stewart AG, Sherry D, Thompson JS, Morice AH. Effects
26 Winter RJ, Zhao L, Krauss T, Hughes JM. Neutral endo-
27 Adams SP, Structure and biologic properties of the atrial
28 Richards AM, Wittert G, Espiner EA, Yandle TG, Framp-
32 Armitage P, Berry G. 9A Regression in groups. In: Statisti-
33 Stewart AG, Bardsole PA, Baudouin SV, Waterhouse JC,
34 Morice AH, Pepeke-Zaba J, Brown MJ, Thomas PS, Higen-
bottam TW. Atrial natriuretic peptide in primary pul-
35 Herrmann HG, Rosenthal AD, Davis CA. Cardiovascular
effects of intracoronary atrial natriuretic peptide adminis-
36 Münzel T, Drexler H, Holtz J, Kurz S, Just H. Mechan-
isms involved in the response to prolonged infusion of atrial natriuretic factor in patients with chronic heart
38 Groban L, Ebert TJ, Kreis DU, Skelton MM, van Wyn-
trations and pulmonary hemodynamics in patients with pul-
42 Kokubu T, Nagae A, Hiwada K, Kazazani Y, Job T, Matsuo H. Pulmonary arterial pressure and plasma concen-
Haemodynamic effects of atrial natriuretic peptide in hypoxic chronic obstructive pulmonary disease.
T K Rogers, W Sheedy, J Waterhouse, P Howard and A H Morice

doi: 10.1136/thx.49.3.233

Updated information and services can be found at:
http://thorax.bmj.com/content/49/3/233

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/